Safety and immunogenicity of the COVID-19 vaccine BNT162b2 for patients with breast and gynecological cancer on active anticancer therapy: Results of a prospective observational study
BackgroundVaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are highly effective. Nevertheless, immunocompromised participants were excluded from randomized controlled clinical trials. This study evaluates the efficacy and safety of the Pfizer/BioNTech BNT162b2 (BNT162b2)...
Main Authors: | Pietro De Placido, Erica Pietroluongo, Carmine De Angelis, Margherita Tafuro, Chiara Barraco, Rosa Giannatiempo, Roberto Buonaiuto, Francesco Schettini, Anna Iervolino, Emilia Anna Vozzella, Mario Giuliano, Roberto Bianco, Grazia Arpino |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-08-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.951026/full |
Similar Items
-
Adverse Events Associated with BNT162b2 and AZD1222 Vaccines in the Real World: Surveillance Report in a Single Italian Vaccine Center
by: Maria Costantino, et al.
Published: (2022-03-01) -
Reduced Antibody Acquisition with Increasing Age following Vaccination with BNT162b2: Results from Two Longitudinal Cohort Studies in The Netherlands
by: Lotus Leonie van den Hoogen, et al.
Published: (2022-09-01) -
Pulmonary Embolism after Vaccination with the COVID-19 Vaccine (Pfizer, BNT162b2): A Case Report
by: Eun-Ju Kim, et al.
Published: (2023-06-01) -
Association between Reactogenicity and Immunogenicity after Vaccination with BNT162b2
by: Stilla Bauernfeind, et al.
Published: (2021-09-01) -
Serological response to a third booster dose of BNT162b2 COVID‐19 vaccine among seronegative cancer patients
by: Einat Shacham Shmueli, et al.
Published: (2022-08-01)